Candel Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
During the three months ended June 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted, terminated or modified a Rule 10b5-1 trading arrangement or any “non-Rule 10b5-1 trading agreement” (as defined in Item 408(c) of Regulation S-K), except as set forth below:
| Name and Position | Action Taken | Type of Plan | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Paul Peter Tak, M.D., Ph.D., FMedSci (Chief Executive Officer, President and Director)* | Modification (June 11, 2026) | Rule 10b5-1 trading arrangement | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Earlier of (i) June 30, 2027 and (ii) the completed sale of the maximum aggregate number of securities under the plan | Up to 280,245 shares |
*Plan adopted March 13, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.